Imaging of bronchial carcinoid tumours with indium-111 pentetreotide
1
434 Abstracts/Lung Cancer 1I (1994) 423-444 lung cancer, serum BFP was measured in 50 patients with primary lung cancer and 40 patients with other non-malignant pulmonary diseases. For comparison, various tumor markets such as CEA, SLX, CA19-9, CA125, TPA, SCC, and NSE were also measured. Jn 58% of the patients with primary lung cancer, BFP was positive. This rate was higher than that of CEA and SLX, but lower than that of TPA. Histologically, BFP tended to occur more frequently in small cell carcinoma and large cell carcinoma. CEA and SLX showed high specificityinadetmcarcinoma, andSCCandNSEshowedhighspecificity in squamous cell carcinoma and small cell carcinoma, respectively. BFP levels tended to be higher in the advanced stages of di- and the change of BFP levels was related to chemotherapeutic response. However this tendency was not observed in patients who did not respond tochemotherapy;thiswasparticularlypronouncedinsmallcellcarcinoma. In the study of various tumor markers, a correlation was observed only between BFP and NSE, which suggests that these two tumor markers are valuable in combination assay. In conclusion, measurement of BFP is a uselitl method of monitoring the effectiveness of treatment in primary lung cancer. Cyfra 21-1, a new marker of lung cancer Grenier J, Pujol JL, Guilleux F, Dames JP, Pujol H, Michel FB. Cl. Regional de Lutte contre Cancer, Laboratoire dc Radioanalysc. 34094 Montpelkir Ceder 5. Nucl Med Biol 1994;21:47 l-6. There are few outstanding serous markers in the treatment of bronchial cancer. ACE lacks sensitivity and specificity and cannot be used as a diagnostic marker. It has been described as a marker of tumoral mass, although not in our study. Pmgnostic significance was observed, butonlyin aunivariateanalysis. SensitivityofSCCTA4variedbetw’eeti studies. In our population, the RGC curve for SCC TA4 showed poor discrimination potential. NSE was shown to be a useful marker in the treatment of patients with small cell cancers. Cytokeratins are expressed by all bronchial cancers. Cytokeratin 19 is a sub-unit detected in simple epithelia and their neoplastic counterparts. During tumoral cell lysis, certain fragments of this cytokeratin may be liberated. The immunoradiometric assay described here is able to detect fragments of cytokeratin 19 (called Cyfra 21-I) in serum. Our study established a correlation between Cyfra 21-I levels and the cancer stage for NCPC, but not for CPC. In addition, Cyfra 21-I concentration may be used as a tumoral mass marker. Patients with high Cyfra 21 levels must undergo special treatment to End remote tumors. Three-step tumor pre-taqeting in lung cancer immunoseintigraphy Dosio F, Magoaoi P, Paganelli G, Samuel A, Chiesa G, Fazio F. Department of Nuclear Medicine, Istituto Sckntifco, Ospedale II San RaJiik, Vlu Olgettinu, 60, I-20132, Milano. J Nucl Biol Med 1993;31:228- 32. Radiolabelled MoAbs have been used in both the diagnosis and the treatment of a variety of tumors. Recently, a three-step tumor pre- targeting strategy has been proposed to overcome one of the major limitingfactorsinradioimmunodetection: thelowtumor-to-background ratio. We evaluated this pre-targeting protocol in 10 patients diagnosed as having pulmonary carcinoma. Gne milligram of biotinylated anti- CEA MoAb (FG23CJ) was administered i.v. (1st step); 24 hours later 5 mg of avidin was injected iv. (2nd step) followed by 100-500 ng of “‘In-biotin (5 mCi) the day after (3rd step). Imaging was performed using single photon emission tomography (SPET). No toxicity and no adverse reactions were observed. Tumor was detected in 8 out of 10 patients. Mediastinal metastases were also localised in 2 out of 3 patients, and adrenal gland recurrency in 1 out of 2 patients. The tumor/ background(normallung), heart, liversndspineratioswererespectively 2.0, 1.0, 1.3 and 4.1 at 90 minutes post-injection. These preliminary data show that the three-step pre-targeting method is safe and allows SPET tumor localization soon after the injection of the radiolabel. In the future, the use of MoAbs with higher specificity could result in improved tumor-targeting, and in the possibility of lung cancer radioimmunotherapy. planar cobalt-57 bleomycin scintigrapby comparedwith CT-scan in the diagnosis and stngittg of lung cnneer Verhoeven GT, Kho GS, Ausema L, Krwming EP, Hilvering C. Departtnent of Pulmonary Medicine. Uniwrsity Hospital Dljkzigt, Dr. Mokwatetplein 40,301s GD Rotterdam. Netb J Med 199444: 116-21. Objectives: Cobalt-57 bleomycin accumulates in tumour cells and is a diagnostic aid for discriminating malignant and.benign lesions. Published data indicate that planar cobalt-57 bleomycin scintigraphy (bleo-scan) is a sensitive and specific test in the diagnosis and staging of lung cancer. CT-scan was however not used in these studies. We tested the value of bleo-scan and compared the results with those of computed tomography (Cf-scan). Methods: Bleo-scan and CT-scan were obtained from patients who were consecutively investigated because of a suspicious lesion on their cheat X-ray. Results: In 59 patients carcinoma of the lung was diagnosed 49 times (83%). The sensitivity of bleo-scan was 90%, specificity was 30% and positive predictive value (PPV) 86 %. CT-scan could not discriminate between malignant and benign lesions. Thirty-two of the 41 patients with non- small-cell lung cancer had pathological examination of mediastinal lymph nodes, revealing metastases in4796 ofthepatients. Bleo-scan and CT-scan, respectively, had a sensitivity of 53 and 8796, a specificity of 77 and 821, and negative predictive values (NPV) of 65 and 87%. In the 49 lung cancer patients distant metastases were detected at 11 sites in 10 patients. Bleo-scan gave false-negative and false-positive results. Conclusions. Bleo-scan in (suspected) lung cancer adds too little to the diagnostic procedure to make it a routine procedure. CT-scan gives indispensable information about possible media&al involvement. Imaging of bronchial carcinoid tumours with indium-111 pentetreotide O’Byme KJ, O’Hare NJ, Freyne PJ, Luke DA, Clancy LJ, P&hard JS et al. ICRF, Clinical Oncology Unit, Churchill Hospital. Headington. oxfrd OX3 RI. Thorax 1994;49:284-6. Neuroendocrine turnouts are charactetised by the expression of high affinity binding sites for somatostatin. The detection of bronchial carcinoid tumours through scintigraphic imaging is described in two patients using the novel radiolabelled somatostatin analogue indium- 111 pentetreotide. Clinical and methodological reliability of an immunotndiometric assay for the new lung cnncer marker: Cyfrn 21-1 RouxN, Roux F, FerrandV, KleisbauerJP.Laborotoirc&R, Hopital de la Conception, 13385 Marseilk Cedex 05. Immtmo-Anal Biol Spec 1994;9:30-9. Cytokeratin 19 (CK 19) is an acidic cytoplasmic protein (intermediate filament) with antigen properties associated to epithelial malignancies, in particular lung cancer. We have used an immunomdiometric assay using two different monc-clonal antibodies (BM 19-21 and KS 19-I) to detect CK 19 serum levels (Elsa Cyfra 21-1, CIS bio international).
Transcript of Imaging of bronchial carcinoid tumours with indium-111 pentetreotide
434 Abstracts/Lung Cancer 1 I (1994) 423-444
lung cancer, serum BFP was measured in 50 patients with primary lung cancer and 40 patients with other non-malignant pulmonary diseases. For comparison, various tumor markets such as CEA, SLX, CA19-9, CA125, TPA, SCC, and NSE were also measured. Jn 58% of the patients with primary lung cancer, BFP was positive. This rate was higher than that of CEA and SLX, but lower than that of TPA. Histologically, BFP tended to occur more frequently in small cell carcinoma and large cell carcinoma. CEA and SLX showed high specificityinadetmcarcinoma, andSCCandNSEshowedhighspecificity in squamous cell carcinoma and small cell carcinoma, respectively. BFP levels tended to be higher in the advanced stages of di- and the change of BFP levels was related to chemotherapeutic response. However this tendency was not observed in patients who did not respond tochemotherapy;thiswasparticularlypronouncedinsmallcellcarcinoma. In the study of various tumor markers, a correlation was observed only between BFP and NSE, which suggests that these two tumor markers are valuable in combination assay. In conclusion, measurement of BFP is a uselitl method of monitoring the effectiveness of treatment in primary lung cancer.
Cyfra 21-1, a new marker of lung cancer Grenier J, Pujol JL, Guilleux F, Dames JP, Pujol H, Michel FB. Cl. Regional de Lutte contre Cancer, Laboratoire dc Radioanalysc. 34094 Montpelkir Ceder 5. Nucl Med Biol 1994;21:47 l-6.
There are few outstanding serous markers in the treatment of bronchial cancer. ACE lacks sensitivity and specificity and cannot be used as a diagnostic marker. It has been described as a marker of tumoral mass, although not in our study. Pmgnostic significance was observed, butonlyin aunivariateanalysis. SensitivityofSCCTA4variedbetw’eeti studies. In our population, the RGC curve for SCC TA4 showed poor discrimination potential. NSE was shown to be a useful marker in the treatment of patients with small cell cancers. Cytokeratins are expressed by all bronchial cancers. Cytokeratin 19 is a sub-unit detected in simple epithelia and their neoplastic counterparts. During tumoral cell lysis, certain fragments of this cytokeratin may be liberated. The immunoradiometric assay described here is able to detect fragments of cytokeratin 19 (called Cyfra 21-I) in serum. Our study established a correlation between Cyfra 21-I levels and the cancer stage for NCPC, but not for CPC. In addition, Cyfra 21-I concentration may be used as a tumoral mass marker. Patients with high Cyfra 21 levels must undergo special treatment to End remote tumors.
Three-step tumor pre-taqeting in lung cancer immunoseintigraphy Dosio F, Magoaoi P, Paganelli G, Samuel A, Chiesa G, Fazio F. Department of Nuclear Medicine, Istituto Sckntifco, Ospedale II San RaJiik, Vlu Olgettinu, 60, I-20132, Milano. J Nucl Biol Med 1993;31:228- 32.
Radiolabelled MoAbs have been used in both the diagnosis and the treatment of a variety of tumors. Recently, a three-step tumor pre- targeting strategy has been proposed to overcome one of the major limitingfactorsinradioimmunodetection: thelowtumor-to-background ratio. We evaluated this pre-targeting protocol in 10 patients diagnosed as having pulmonary carcinoma. Gne milligram of biotinylated anti- CEA MoAb (FG23CJ) was administered i.v. (1st step); 24 hours later 5 mg of avidin was injected iv. (2nd step) followed by 100-500 ng of “‘In-biotin (5 mCi) the day after (3rd step). Imaging was performed using single photon emission tomography (SPET). No toxicity and no adverse reactions were observed. Tumor was detected in 8 out of 10 patients. Mediastinal metastases were also localised in 2 out of 3 patients, and adrenal gland recurrency in 1 out of 2 patients. The tumor/
background(normallung), heart, liversndspineratioswererespectively 2.0, 1.0, 1.3 and 4.1 at 90 minutes post-injection. These preliminary data show that the three-step pre-targeting method is safe and allows SPET tumor localization soon after the injection of the radiolabel. In the future, the use of MoAbs with higher specificity could result in improved tumor-targeting, and in the possibility of lung cancer radioimmunotherapy.
planar cobalt-57 bleomycin scintigrapby comparedwith CT-scan in the diagnosis and stngittg of lung cnneer Verhoeven GT, Kho GS, Ausema L, Krwming EP, Hilvering C. Departtnent of Pulmonary Medicine. Uniwrsity Hospital Dljkzigt, Dr. Mokwatetplein 40,301s GD Rotterdam. Netb J Med 199444: 116-21.
Objectives: Cobalt-57 bleomycin accumulates in tumour cells and is a diagnostic aid for discriminating malignant and.benign lesions. Published data indicate that planar cobalt-57 bleomycin scintigraphy (bleo-scan) is a sensitive and specific test in the diagnosis and staging of lung cancer. CT-scan was however not used in these studies. We tested the value of bleo-scan and compared the results with those of computed tomography (Cf-scan). Methods: Bleo-scan and CT-scan were obtained from patients who were consecutively investigated because of a suspicious lesion on their cheat X-ray. Results: In 59 patients carcinoma of the lung was diagnosed 49 times (83%). The sensitivity of bleo-scan was 90%, specificity was 30% and positive predictive value (PPV) 86 %. CT-scan could not discriminate between malignant and benign lesions. Thirty-two of the 41 patients with non- small-cell lung cancer had pathological examination of mediastinal lymph nodes, revealing metastases in4796 ofthepatients. Bleo-scan and CT-scan, respectively, had a sensitivity of 53 and 8796, a specificity of 77 and 821, and negative predictive values (NPV) of 65 and 87%. In the 49 lung cancer patients distant metastases were detected at 11 sites in 10 patients. Bleo-scan gave false-negative and false-positive results. Conclusions. Bleo-scan in (suspected) lung cancer adds too little to the diagnostic procedure to make it a routine procedure. CT-scan gives indispensable information about possible media&al involvement.
Imaging of bronchial carcinoid tumours with indium-111 pentetreotide O’Byme KJ, O’Hare NJ, Freyne PJ, Luke DA, Clancy LJ, P&hard JS et al. ICRF, Clinical Oncology Unit, Churchill Hospital. Headington. oxfrd OX3 RI. Thorax 1994;49:284-6.
Neuroendocrine turnouts are charactetised by the expression of high affinity binding sites for somatostatin. The detection of bronchial carcinoid tumours through scintigraphic imaging is described in two patients using the novel radiolabelled somatostatin analogue indium- 111 pentetreotide.
Clinical and methodological reliability of an immunotndiometric assay for the new lung cnncer marker: Cyfrn 21-1 RouxN, Roux F, FerrandV, KleisbauerJP.Laborotoirc&R, Hopital de la Conception, 13385 Marseilk Cedex 05. Immtmo-Anal Biol Spec 1994;9:30-9.
Cytokeratin 19 (CK 19) is an acidic cytoplasmic protein (intermediate filament) with antigen properties associated to epithelial malignancies, in particular lung cancer. We have used an immunomdiometric assay using two different monc-clonal antibodies (BM 19-21 and KS 19-I) to detect CK 19 serum levels (Elsa Cyfra 21-1, CIS bio international).
